SpringWorks Therapeutics Profit Margin

The latest profit margin for SWTX is -115.6% as of March 2025. That compares with -895.42% in the prior-year period — up 87.1% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside SpringWorks Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SWTX's profit margin moved from -895.42% to -115.6% — a 87.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SpringWorks Therapeutics's valuation or profitability profile.

Against Healthcare companies, SWTX currently prints -115.6% for profit margin, while the sector average sits near 14.41%. That is roughly 901.9% below the sector mean. Large gaps often invite a closer look at SpringWorks Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively SpringWorks Therapeutics converts resources into returns. At -115.6%, SWTX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -895.42% in the prior-year period — up 87.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting SWTX's profit margin (-115.6%), review year-over-year change from -895.42%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.